SynthesisBMC cardiovascular disorders2026
Association of MTHFR C677T polymorphism with risk of atherosclerotic cardiovascular diseases: a systematic review and meta-analysis.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough several meta-analyses have examined the association between MTHFR C677T and specific cardiovascular outcomes, a comprehensive evaluation focusing on atherosclerotic cardiovascular disease (ASCVD) as a unified outcome, incorporating recently published studies (January 2016-March 2026), remains limited.
methodsPotential studies were selected from Embase, Web of Science, and PubMed databases. Pooled effect size was evaluated by odds ratios (ORs) with 95% confidence intervals (CIs) using random-effects models where significant heterogeneity was present.
resultsTwenty-three case-control studies (including 6693 patients and 7692 controls) from January 2016 to March 2026 were enrolled in this study. Significant heterogeneity was observed across models (I² > 50%, all p
conclusionsMTHFR C677T was positively correlated with ASCVD risk across multiple genetic models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.